Madoka Iida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Madoka Iida has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Masahisa Katsuno
Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan
8 shared publications - Kentaro Sahashi
Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
3 shared publications Kazunari Onodera
Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
2 shared publicationsKenji Sakakibara
Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
2 shared publicationsKentaro Maeda
Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
2 shared publicationsTomoki Hirunagi
Nagoya University Graduate School of Medicine, Tokai National Higher Education and Research System 1 Department of Neurology 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550
2 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 14 (6) , 497-499
Management of Refractory Thymoma‐Associated Myasthenia Gravis With Sequential FcRn Antagonist and Complement Inhibition Combined With Resection of Pleural Dissemination
Myasthenia gravis (MG) associated with disseminated thymoma is often refractory to conventional treatments due to continuous autoantibody production. The optimal treatment strategy, particularly the combination of complement component 5 (C5) inhibitor, neonatal Fc receptor (FcRn) antagonist, and surgical resection in thymoma‐associated myasthenic crisis, remains to be established. A 48‐year‐old man with Masaoka stage IVa thymoma developed an immunotherapy‐resistant myasthenic crisis. He was treated with a neonatal Fc receptor (FcRn) antagonist followed by a complement component 5 inhibitor, alongside repeated surgical resections of pleural implants. This strategy facilitated a persistent decline in anti‐acetylcholine receptor antibody titers and clinical remission despite the persistence of residual tumor. This case suggests that in MG associated with Masaoka stage IVa thymoma and pleural dissemination, the combination of FcRn antagonists, C5 inhibitors, and repeated surgical resection when feasible may contribute to providing an avenue from crisis to long‐term disease control.
- 20 July 2026
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 14 (6) , 497-499
Open AccessManagement of Refractory Thymoma‐Associated Myasthenia Gravis With Sequential FcRn Antagonist and Complement Inhibition Combined With Resection of Pleural Dissemination
Myasthenia gravis (MG) associated with disseminated thymoma is often refractory to conventional treatments due to continuous autoantibody production. The optimal treatment strategy, particularly the combination of complement component 5 (C5) inhibitor, neonatal Fc receptor (FcRn) antagonist, and surgical resection in thymoma‐associated myasthenic crisis, remains to be established. A 48‐year‐old man with Masaoka stage IVa thymoma developed an immunotherapy‐resistant myasthenic crisis. He was treated with a neonatal Fc receptor (FcRn) antagonist followed by a complement component 5 inhibitor, alongside repeated surgical resections of pleural implants. This strategy facilitated a persistent decline in anti‐acetylcholine receptor antibody titers and clinical remission despite the persistence of residual tumor. This case suggests that in MG associated with Masaoka stage IVa thymoma and pleural dissemination, the combination of FcRn antagonists, C5 inhibitors, and repeated surgical resection when feasible may contribute to providing an avenue from crisis to long‐term disease control.
- Open Access
- 27 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2412
Restoring early postnatal synaptic dysregulation rescues motor neuron degeneration in a mouse model of Spinal and Bulbar Muscular Atrophy
Spinal and bulbar muscular atrophy (SBMA) is an adult-onset neurodegenerative disorder caused by expansion of a polyglutamine tract in the androgen receptor (AR). Here, we show that polyglutamine-expanded AR accumulates in the nucleus of motor neurons and induces aberrant upregulation of glutamatergic synaptic genes through dysfunction of the master transcriptional repressor REST during early postnatal development in a mouse model of SBMA (AR-97Q mice). Reducing mutant AR or restoring REST function using antisense oligonucleotides during the neonatal period attenuated the upregulation of glutamatergic synaptic genes and ameliorated the disease phenotype and histopathology in AR-97Q mice. Furthermore, we observed increased calcium activity in induced pluripotent stem cell-derived motor neurons from SBMA patients compared to those from healthy controls, reflecting neuronal hyperexcitability. Late-onset neurodegeneration in SBMA is attributable to early synaptic defects and the resulting hyperexcitability of motor neurons, which may represent therapeutic targets.
- 27 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 2412
Open AccessRestoring early postnatal synaptic dysregulation rescues motor neuron degeneration in a mouse model of Spinal and Bulbar Muscular Atrophy
Spinal and bulbar muscular atrophy (SBMA) is an adult-onset neurodegenerative disorder caused by expansion of a polyglutamine tract in the androgen receptor (AR). Here, we show that polyglutamine-expanded AR accumulates in the nucleus of motor neurons and induces aberrant upregulation of glutamatergic synaptic genes through dysfunction of the master transcriptional repressor REST during early postnatal development in a mouse model of SBMA (AR-97Q mice). Reducing mutant AR or restoring REST function using antisense oligonucleotides during the neonatal period attenuated the upregulation of glutamatergic synaptic genes and ameliorated the disease phenotype and histopathology in AR-97Q mice. Furthermore, we observed increased calcium activity in induced pluripotent stem cell-derived motor neurons from SBMA patients compared to those from healthy controls, reflecting neuronal hyperexcitability. Late-onset neurodegeneration in SBMA is attributable to early synaptic defects and the resulting hyperexcitability of motor neurons, which may represent therapeutic targets.
- Open Access
- 4 December 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (12) , e70457
Bone Fragility and Fracture Characteristics in Patients With Spinal and Bulbar Muscular Atrophy
Background: Spinal and bulbar muscular atrophy (SBMA) is a hereditary neuromuscular disorder linked to androgen receptor gene mutations, often associated with metabolic abnormalities. We aimed to investigate the incidence of fragility fractures and the underlying mechanisms in SBMA. Methods: Consecutive genetically confirmed SBMA patients and healthy controls (HC) were enrolled. We surveyed fracture history and assessed motor function, bone metabolism markers, and bone mineral density (BMD) using dual‐energy X‐ray absorptiometry. Longitudinal BMD changes were also analyzed between SBMA patients and HC. Results: A total of 109 SBMA patients and 21 HC were included. Fragility fractures in SBMA patients were mainly observed in cortical bone‐dominant regions. Their lower limb BMD was significantly reduced (SBMA 1.10 g/cm, HC 1.19 g/cm; p < 0.05) and further decreased overtime. Despite low bone resorption markers, bone formation markers showed no difference between the groups, suggesting that SBMA patients exhibit characteristics of low turnover osteoporosis. Serum 25‐hydroxyvitamin D levels were lower in SBMA patients than in HC (15.4 ng/mL vs. 19.4 ng/mL; p < 0.01). Longitudinal analysis revealed that SBMA patients had a higher incidence of fragility fractures than HC (log‐rank test, p < 0.05), with the first fragility fracture occurring 10 years after the onset of muscle weakness. Low baseline BMD was a predictor of fragility fractures (adjusted OR = 0.32; 95% CI: 0.17–0.60; p < 0.05). Conclusions: SBMA patients have a high fragility fracture incidence, particularly in cortical bone, with a progressive BMD decrease. Low bone turnover and vitamin D deficiency are associated with these fractures.
- 4 December 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (12) , e70457
Open AccessBone Fragility and Fracture Characteristics in Patients With Spinal and Bulbar Muscular Atrophy
Background: Spinal and bulbar muscular atrophy (SBMA) is a hereditary neuromuscular disorder linked to androgen receptor gene mutations, often associated with metabolic abnormalities. We aimed to investigate the incidence of fragility fractures and the underlying mechanisms in SBMA. Methods: Consecutive genetically confirmed SBMA patients and healthy controls (HC) were enrolled. We surveyed fracture history and assessed motor function, bone metabolism markers, and bone mineral density (BMD) using dual‐energy X‐ray absorptiometry. Longitudinal BMD changes were also analyzed between SBMA patients and HC. Results: A total of 109 SBMA patients and 21 HC were included. Fragility fractures in SBMA patients were mainly observed in cortical bone‐dominant regions. Their lower limb BMD was significantly reduced (SBMA 1.10 g/cm, HC 1.19 g/cm; p < 0.05) and further decreased overtime. Despite low bone resorption markers, bone formation markers showed no difference between the groups, suggesting that SBMA patients exhibit characteristics of low turnover osteoporosis. Serum 25‐hydroxyvitamin D levels were lower in SBMA patients than in HC (15.4 ng/mL vs. 19.4 ng/mL; p < 0.01). Longitudinal analysis revealed that SBMA patients had a higher incidence of fragility fractures than HC (log‐rank test, p < 0.05), with the first fragility fracture occurring 10 years after the onset of muscle weakness. Low baseline BMD was a predictor of fragility fractures (adjusted OR = 0.32; 95% CI: 0.17–0.60; p < 0.05). Conclusions: SBMA patients have a high fragility fracture incidence, particularly in cortical bone, with a progressive BMD decrease. Low bone turnover and vitamin D deficiency are associated with these fractures.
- Open Access
- 1 June 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (6)
Label-free morphology-based phenotypic analysis of spinal and bulbar muscular atrophy muscle cell models
Spinal and bulbar muscular atrophy (SBMA) is a neuromuscular disorder caused by CAG trinucleotide expansion in the androgen receptor (AR) gene. To improve the quality of in vitro cell-based assays for the evaluation of potential drug candidates for SBMA, we developed a morphology-based phenotypic analysis for a muscle cell model of SBMA that involves multiparametric morphological profiling to quantitatively assess the therapeutic effects of drugs on muscle cell phenotype. The analysis was validated using dihydrotestosterone and pioglitazone, which have been shown to exacerbate and ameliorate the pathophysiology of SBMA, respectively. Gene expression analysis revealed activation of the JNK pathway in the SBMA cells compared to the control cells. Phenotypic analysis revealed the effect of naratriptan, a JNK inhibitor, on the phenotypic changes of SBMA cells, and the results were confirmed by LDH assays. We then trained a predictive machine learning model to classify the drug responses, and it successfully discriminated between pioglitazone-type and naratriptan-type morphological profiles based on their morphological characteristics. Our morphology-based phenotypic analysis provides a noninvasive and efficient screening method to accelerate the development of therapeutics for SBMA.
- 1 June 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (6)
Open AccessLabel-free morphology-based phenotypic analysis of spinal and bulbar muscular atrophy muscle cell models
Spinal and bulbar muscular atrophy (SBMA) is a neuromuscular disorder caused by CAG trinucleotide expansion in the androgen receptor (AR) gene. To improve the quality of in vitro cell-based assays for the evaluation of potential drug candidates for SBMA, we developed a morphology-based phenotypic analysis for a muscle cell model of SBMA that involves multiparametric morphological profiling to quantitatively assess the therapeutic effects of drugs on muscle cell phenotype. The analysis was validated using dihydrotestosterone and pioglitazone, which have been shown to exacerbate and ameliorate the pathophysiology of SBMA, respectively. Gene expression analysis revealed activation of the JNK pathway in the SBMA cells compared to the control cells. Phenotypic analysis revealed the effect of naratriptan, a JNK inhibitor, on the phenotypic changes of SBMA cells, and the results were confirmed by LDH assays. We then trained a predictive machine learning model to classify the drug responses, and it successfully discriminated between pioglitazone-type and naratriptan-type morphological profiles based on their morphological characteristics. Our morphology-based phenotypic analysis provides a noninvasive and efficient screening method to accelerate the development of therapeutics for SBMA.
- 3 May 2023
- Published by Elsevier in Neuroscience Research
- Vol. 194, 58-65
Dysregulation of Aldh1a2 underlies motor neuron degeneration in spinal muscular atrophy
- 3 May 2023
- Published by Elsevier in Neuroscience Research
- Vol. 194, 58-65
Dysregulation of Aldh1a2 underlies motor neuron degeneration in spinal muscular atrophy
- Open Access
- 1 June 2021
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 24, 1-10
Selective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS
- 1 June 2021
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 24, 1-10
Open AccessSelective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS
- Open Access
- 20 November 2019
- Published by Springer Nature in Research Square
Immunoprecipitation of protein lysate from culture cells using Src antibody
It is a procedure for immunoprecipitation using protein lysate from a neuronal cell line, NSC34, and a muscle cell line, C2C12 using DynabeadsTM Protein G Immunoprecipitation Kit (ThermoFisher).
- 20 November 2019
- Published by Springer Nature in Research Square
Open AccessImmunoprecipitation of protein lysate from culture cells using Src antibody
It is a procedure for immunoprecipitation using protein lysate from a neuronal cell line, NSC34, and a muscle cell line, C2C12 using DynabeadsTM Protein G Immunoprecipitation Kit (ThermoFisher).
- Open Access
- 20 November 2019
- Published by Springer Nature in Research Square
Bio-Plex phosphoprotein assay using spinal cords and skeletal muscles of mice
Bio-Plex phosphoprotein assays are magnetic bead-based immunoassays for the detection of intracellular phosphoproteins in cell and tissue lysates. The assay can be readily multiplexed to simultaneously examine the expression levels of numerous phosphorylated proteins.
- 20 November 2019
- Published by Springer Nature in Research Square
Open AccessBio-Plex phosphoprotein assay using spinal cords and skeletal muscles of mice
Bio-Plex phosphoprotein assays are magnetic bead-based immunoassays for the detection of intracellular phosphoproteins in cell and tissue lysates. The assay can be readily multiplexed to simultaneously examine the expression levels of numerous phosphorylated proteins.